Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Watson Confirms Exalgo™ Patent Challenge

By Pharmaceutical Processing | December 15, 2010

Watson Pharmaceuticals, Inc. has confirmed that its
subsidiary, Watson Laboratories, Inc. – Florida,
filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval
to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg,
and 16 mg. Watson’s Hydromorphone Hydrochloride Extended-release Tablets are a
generic version of Mallinckrodt Inc.’s Exalgo™ tablets, which are indicated for
once daily administration for the management of moderate to severe pain in
opioid tolerant patients requiring continuous, around-the-clock opioid
analgesia for an extended period of time.

Mallinckrodt filed suit against Watson on December 10, 2010
in the United States District Court for the District of New Jersey seeking to
prevent Watson from commercializing its product prior to the expiration of U.S.
Patent No. 5,914,131. Mallinckrodt’s lawsuit was filed under the provisions of
the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson’s
ANDA until April 29, 2013, or until final resolution of the matter before the
court, whichever occurs sooner, subject to any other exclusivities.  

Based on available information, Watson believes it may be a
“first applicant” to file an ANDA for the 8 mg, 12 mg, and 16 mg
generic versions of Exalgo™ and, should its ANDA be approved, may be entitled
to 180 days of generic market exclusivity.

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards